PMID- 25285355
OWN - NLM
STAT- MEDLINE
DCOM- 20150911
LR  - 20211021
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Print)
IS  - 1396-0296 (Linking)
VI  - 28
IP  - 1
DP  - 2015 Jan-Feb
TI  - Combination of everolimus and tacrolimus: a potentially effective regimen for 
      recalcitrant psoriasis.
PG  - 25-7
LID - 10.1111/dth.12176 [doi]
AB  - Severe forms of psoriasis that are refractory to conventional therapies are often 
      difficult to manage. The mammalian target of rapamycin (mTOR) inhibitors 
      potentially have versatile effects toward putative psoriatic pathologic pathways. 
      Therefore, mTOR inhibitors may offer a range of new therapeutic options for 
      patients with psoriasis. We describe a 55-year-old male renal transplant patient 
      with refractory psoriasis. We adjusted his antirejection regimen and put him on 
      everolimus (Certican((R)); Novartis, Basel, Switzerland; a semisynthetic macrolide, 
      belonging to the mTOR inhibitors family) with low-dose tacrolimus. This 
      combination regimen maintained his graft function and successfully controlled his 
      psoriasis. His skin lesions never recurred in the next 18 months. To our 
      knowledge, this is the first report showing that the combination of everolimus 
      and tacrolimus could be used to treat recalcitrant psoriasis. The relative 
      benefit-risk profiles of such therapies worth further investigation.
CI  - (c) 2014 The Authors. Dermatologic Therapy Published by Wiley Periodicals, Inc.
FAU - Wei, Kai-Che
AU  - Wei KC
AD  - Department of Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung, 
      Taiwan.
FAU - Lai, Ping-Chin
AU  - Lai PC
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20141006
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 0 (Immunosuppressive Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - W36ZG6FT64 (Sirolimus)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Drug Therapy, Combination
MH  - Everolimus
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage/pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/*drug therapy/pathology
MH  - Severity of Illness Index
MH  - Sirolimus/administration & dosage/*analogs & derivatives/pharmacology/therapeutic 
      use
MH  - Tacrolimus/administration & dosage/pharmacology/*therapeutic use
MH  - Treatment Outcome
PMC - PMC4309507
OTO - NOTNLM
OT  - everolimus
OT  - mTOR inhibitor
OT  - psoriasis
OT  - tacrolimus
EDAT- 2014/10/07 06:00
MHDA- 2015/09/12 06:00
CRDT- 2014/10/07 06:00
PHST- 2014/10/07 06:00 [entrez]
PHST- 2014/10/07 06:00 [pubmed]
PHST- 2015/09/12 06:00 [medline]
AID - 10.1111/dth.12176 [doi]
PST - ppublish
SO  - Dermatol Ther. 2015 Jan-Feb;28(1):25-7. doi: 10.1111/dth.12176. Epub 2014 Oct 6.